About all

Can a diabetic be an organ donor. Organ Donation for Diabetics: Possibilities and Research Implications

by alexxlab

Can diabetics be organ donors after death. How does insulin dependency affect organ donation eligibility. What insights can diabetic organ donors provide for type 1 diabetes research. What are the screening procedures for potential diabetic organ donors. How do researchers analyze pancreatic tissue from diabetic donors. What are the challenges in collecting high-quality pancreatic samples from donors.

The Potential of Diabetic Organ Donors

The question of whether diabetics, particularly those who are insulin-dependent, can be organ donors after death is a topic of significant interest in the medical community. Not only does it address the possibility of expanding the pool of potential organ donors, but it also opens up valuable research opportunities in the field of diabetes.

Diabetics, including those with insulin dependency, can indeed be organ donors after death. However, the suitability of their organs for transplantation depends on various factors, including the overall health of the organs and the specific requirements of the recipient.

Organ Donation Eligibility for Diabetics

Are there specific criteria for diabetic organ donors? While diabetes may affect certain organs, it doesn’t necessarily disqualify a person from being an organ donor. Each potential donor is evaluated on a case-by-case basis. Organs that may not be suitable for transplantation could still be valuable for research purposes, particularly in advancing our understanding of type 1 diabetes.

The Role of Organ Donors in Type 1 Diabetes Research

Organ donor specimens, especially from individuals with diabetes, play a crucial role in advancing our understanding of type 1 diabetes. These specimens provide researchers with invaluable insights into the disease’s progression and mechanisms.

The Network for Pancreatic Organ Donors with Diabetes (nPOD)

How does nPOD contribute to diabetes research? The Network for Pancreatic Organ Donors with Diabetes (nPOD) is a groundbreaking program that collects and characterizes pancreatic and related tissues from organ donors with type 1 diabetes, islet autoantibody-positive individuals, and healthy controls. This initiative has significantly advanced our understanding of the disease by providing researchers with high-quality, well-characterized tissue samples for study.

Screening Procedures for Diabetic Organ Donors

Screening potential organ donors for diabetes-related factors is a critical step in both the organ donation process and diabetes research. This screening process involves various tests and assessments to determine the suitability of the organs for transplantation or research.

Islet Autoantibody Testing

What role do islet autoantibodies play in screening diabetic organ donors? Islet autoantibodies are important markers of type 1 diabetes. Screening for these antibodies in organ donors can help identify individuals who may have been in the early stages of developing type 1 diabetes, even if they hadn’t been diagnosed. This information is valuable for both transplantation decisions and research purposes.

Rapid assays have been developed to detect anti-islet autoantibodies, allowing for efficient screening of organ donors. These tests can provide crucial information about the donor’s diabetes status and the potential suitability of their organs for transplantation or research.

Analyzing Pancreatic Tissue from Diabetic Donors

The analysis of pancreatic tissue from diabetic donors provides researchers with unique insights into the pathology of type 1 diabetes. This process involves various techniques and considerations to ensure the collection of high-quality, informative samples.

Histological Examination

How do researchers examine pancreatic tissue from diabetic donors? Histological examination is a key technique used to study pancreatic tissue. This involves preparing thin sections of the tissue, staining them with specific dyes or antibodies, and examining them under a microscope. Researchers can identify and characterize different cell types, including insulin-producing beta cells, and observe any abnormalities or signs of autoimmune attack.

Specific staining protocols have been developed for human pancreatic islets, allowing for detailed visualization and analysis of these crucial structures. These techniques can reveal important information about the distribution and health of different cell types within the islets.

Challenges in Pancreatic Tissue Collection

Collecting high-quality pancreatic tissue samples from organ donors presents several challenges. These challenges can impact the quality and usefulness of the samples for research purposes.

Time-Sensitive Collection

Why is timing crucial in pancreatic tissue collection? The pancreas is particularly sensitive to degradation after death. Researchers must collect and process the tissue as quickly as possible to preserve its structural integrity and biological information. Delays in tissue collection can lead to autolysis, which can significantly impact the quality of the samples and the data that can be obtained from them.

To address this challenge, protocols have been developed for rapid tissue collection and preservation. These protocols aim to minimize the time between organ retrieval and tissue processing, helping to ensure the highest possible sample quality.

Genetic Factors in Type 1 Diabetes Research

Genetic analysis of tissue from diabetic organ donors can provide valuable insights into the genetic factors contributing to type 1 diabetes. This research helps in understanding the complex interplay between genetic predisposition and environmental factors in the development of the disease.

HLA Typing

What is the significance of HLA typing in diabetes research? Human Leukocyte Antigen (HLA) typing is an important aspect of genetic analysis in type 1 diabetes research. Certain HLA types are associated with an increased risk of developing the disease. By analyzing the HLA types of organ donors, researchers can gain insights into the genetic risk factors and potentially identify new genetic markers associated with type 1 diabetes.

This genetic information, when combined with histological and functional data from the pancreatic tissue, can provide a more comprehensive understanding of the disease process and potentially lead to new therapeutic strategies.

Impact of Brain Death on Pancreatic Tissue

The process of brain death can have significant effects on pancreatic tissue, which is an important consideration in both organ transplantation and diabetes research. Understanding these effects is crucial for interpreting research findings and assessing the suitability of organs for transplantation.

Inflammatory Response

How does brain death affect pancreatic tissue? Brain death can trigger a systemic inflammatory response that affects various organs, including the pancreas. This inflammatory activity can lead to changes in the pancreatic tissue that may impact its function and viability. Researchers must take these potential changes into account when analyzing tissue samples from brain-dead donors.

Studies have been conducted to characterize the inflammatory changes that occur in pancreatic tissue following brain death. This research helps in developing strategies to mitigate the effects of inflammation and improve the quality of pancreatic tissue for both transplantation and research purposes.

In conclusion, the ability of diabetics to be organ donors after death not only expands the potential donor pool but also provides invaluable opportunities for advancing our understanding of type 1 diabetes. Through careful screening, rapid tissue collection, and sophisticated analysis techniques, researchers can gain crucial insights into the disease process, potentially leading to new diagnostic tools and therapeutic approaches. While challenges exist in collecting and analyzing pancreatic tissue from diabetic donors, ongoing research and improved protocols continue to enhance our ability to glean important information from these valuable specimens.

Organ donor specimens: What can they tell us about type 1 diabetes?

1. Craig ME, Jefferies C, Dabelea D, Balde N, Seth A, Donaghue KC. Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2014;15(Suppl. 20):4–17. [PubMed] [Google Scholar]

2. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383:69–82. [PMC free article] [PubMed] [Google Scholar]

3. Tran F, Stone M, Huang CY, et al. Population-based incidence of diabetes in Australian youth aged 10–18 yr: increase in type 1 diabetes but not type 2 diabetes. Pediatr Diabetes. 2014;15:585–590. [PubMed] [Google Scholar]

4. Todd JA. Etiology of type 1 diabetes. Immunity. 2010;32:457–467. [PubMed] [Google Scholar]

5. Malaisse WJ, Maedler K. Imaging of the β-cells of the islets of Langerhans. Diabetes Res Clin Pract. 2012;98:11–18. [PubMed] [Google Scholar]

6. Imagawa A, Hanafusa T, Tamura S, et al. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes: close correlation between serological markers and histological evidence of cellular autoimmunity. Diabetes. 2001;50:1269–1273. [PubMed] [Google Scholar]

7. Krogvold L, Edwin B, Buanes T, et al. Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia. 2014;57:841–843. [PubMed] [Google Scholar]

8. Campbell-Thompson M, Wasserfall C, Kaddis J, et al. Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev. 2012;28:608–617. [PMC free article] [PubMed] [Google Scholar]

9. Gianani R, Putnam A, Still T, et al. Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies. J Clin Endocrinol Metab. 2006;91:1855–1861. [PubMed] [Google Scholar]

10. In’t Veld P, Lievens D, De Grijse J, et al. Screening for insulitis in adult autoantibody-positive organ donors. Diabetes. 2007;56:2400–2404. [PubMed] [Google Scholar]

11. Tauriainen S, Salmela K, Rantala I, Knip M, Hyöty H. Collecting high-quality pancreatic tissue for experimental study from organ donors with signs of β-cell autoimmunity. Diabetes Metab Res Rev. 2010;26:585–592. [PubMed] [Google Scholar]

12. Pugliese A, Yang M, Kusmarteva I, et al. The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. Pediatr Diabetes. 2014;15:1–9. [PMC free article] [PubMed] [Google Scholar]

13. Pugliese A, Vendrame F, Reijonen H, Atkinson MA, Campbell-Thompson M, Burke GW. New insight on human type 1 diabetes biology: nPOD and nPOD-transplantation. Curr Diab Rep. 2014;14:530. [PMC free article] [PubMed] [Google Scholar]

14. Maniatis AK, Yu L, Miao D, Nelson K, Eisenbarth GS. Rapid assays for detection of anti-islet autoantibodies: implications for organ donor screening. J Autoimmun. 2001;16:71–76. [PubMed] [Google Scholar]

15. Diamantopoulos S, Allende G, Ferreira J, Ciancio G, Burke G, Pugliese A. Retrospective assessment of islet cell autoantibodies in pancreas organ donors. Diabetes Care. 2008;31:1741–1742. [PMC free article] [PubMed] [Google Scholar]

16. Winter WE, Harris N, Schatz D. Type 1 diabetes islet autoantibody markers. Diabetes Technol Ther. 2002;4:817–839. [PubMed] [Google Scholar]

17. Campbell-Thompson ML, Heiple T, Montgomery E, Zhang L, Schneider L. Staining protocols for human pancreatic islets. J Vis Exp. 2012;63:4068. [PMC free article] [PubMed] [Google Scholar]

18. Bommer G, Friedl U, Heitz PU, Klöppel G. Pancreatic PP cell distribution and hyperplasia. Immunocytochemical morphology in the normal human pancreas, in chronic pancreatitis and pancreatic carcinoma. Virchows Arch A Pathol Anat Histol. 1980;387:319–331. [PubMed] [Google Scholar]

19. Uchida T, Takada T, Ammori BJ, Suda K, Takahashi T. Three-dimensional reconstruction of the ventral and dorsal pancreas: a new insight into anatomy and embryonic development. J Hepatobiliary Pancreat Surg. 1999;6:176–180. [PubMed] [Google Scholar]

20. Noble JA, Erlich HA. Genetics of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2:a007732. [PMC free article] [PubMed] [Google Scholar]

21. Stamm BH. Incidence and diagnostic significance of minor pathologic changes in the adult pancreas at autopsy: a systematic study of 112 autopsies in patients without known pancreatic disease. Hum Pathol. 1984;15:677–683. [PubMed] [Google Scholar]

22. Rudloff U, Bhanot U, Gerald W, et al. Biobanking of human pancreas cancer tissue: impact of ex-vivo procurement times on RNA quality. Ann Surg Oncol. 2010;17:2229–2236. [PMC free article] [PubMed] [Google Scholar]

23. Rech TH, Crispim D, Rheinheimer J, et al. Brain death-induced inflammatory activity in human pancreatic tissue: a case-control study. Transplantation. 2014;97:212–219. [PubMed] [Google Scholar]

24. In’t Veld P, De Munck N, Van Belle K, et al. Beta-cell replication is increased in donor organs from young patients after prolonged life support. Diabetes. 2010;59:1702–1708. [PMC free article] [PubMed] [Google Scholar]

25. Rodriguez-Calvo T, Ekwall O, Amirian N, Zapardiel-Gonzalo J, von Herrath MG. Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes. Diabetes. 2014;38:476–481. [PMC free article] [PubMed] [Google Scholar]

26. Campbell-Thompson ML, Atkinson MA, Butler AE, et al. The diagnosis of insulitis in human type 1 diabetes. Diabetologia. 2013;56:2541–2543. [PubMed] [Google Scholar]

27. In’t Veld P. Insulitis in human type 1 diabetes: the quest for an elusive lesion. Islets. 2011;3:131–138. [PMC free article] [PubMed] [Google Scholar]

28. Oram RA, McDonald TJ, Shields BM, et al. Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. Diabetes Care. 2014;38:323–328. [PMC free article] [PubMed] [Google Scholar]

29. Davis AK, DuBose SN, Haller MJ, et al. Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care. 2014;38:476–481. [PubMed] [Google Scholar]

30. Liu EH, Digon BJ, Hirshberg B, et al. Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft. Diabetologia. 2009;52:1369–1380. [PMC free article] [PubMed] [Google Scholar]

31. Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59:2846–2853. [PMC free article] [PubMed] [Google Scholar]

32. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965;14:619–633. [PubMed] [Google Scholar]

33. Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia. 1986;29:267–274. [PubMed] [Google Scholar]

34. Kloppel G, Clemens A. Insulin-dependent diabetes mellitus: islet changes in relation to etiology and pathogenesis. Endocr Pathol. 1997;8:273–282. [PubMed] [Google Scholar]

35. Battaglia M, Atkinson MA. The streetlight effect in type 1 diabetes. Diabetes. 2015;64:1081–1090. [PMC free article] [PubMed] [Google Scholar]

36. Gianani R, Campbell-Thompson M, Sarkar SA, et al. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia. 2010;53:690–698. [PubMed] [Google Scholar]

37. Coppieters KT, Dotta F, Amirian N, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012;209:51–60. [PMC free article] [PubMed] [Google Scholar]

38. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 2011;39:D913–D919. [PMC free article] [PubMed] [Google Scholar]

39. Pipeleers D, In’t Veld P, Pipeleers-Marichal M, Gorus F. The beta cell population in type 1 diabetes. Novartis Found Symp. 2008;292:19–24. discussion 24–31, 122–129, 202–203. [PubMed] [Google Scholar]

40. Löhr M, Klöppel G. Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia. 1987;30:757–762. [PubMed] [Google Scholar]

41. Gregg BE, Moore PC, Demozay D, et al. Formation of a human β-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab. 2012;97:3197–3206. [PMC free article] [PubMed] [Google Scholar]

42. Kilimnik G, Jo J, Periwal V, Zielinski MC, Hara M. Quantification of islet size and architecture. Islets. 2012;4:167–172. [PMC free article] [PubMed] [Google Scholar]

43. Brissova M, Fowler MJ, Nicholson WE, et al. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem. 2005;53:1087–1097. [PubMed] [Google Scholar]

44. Ehrie MG, Swartz FJ. Diploid, tetraploid and octaploid beta cells in the islets of Langerhans of the normal human pancreas. Diabetes. 1974;23:583–588. [PubMed] [Google Scholar]

45. Butler AE, Galasso R, Meier JJ, Basu R, Rizza RA, Butler PC. Modestly increased beta cell apoptosis but no increased beta cell replication in recent-onset type 1 diabetic patients who died of diabetic ketoacidosis. Diabetologia. 2007;50:2323–2331. [PubMed] [Google Scholar]

46. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Evidence of increased islet cell proliferation in patients with recent-onset type 1 diabetes. Diabetologia. 2010;53:2020–2028. [PubMed] [Google Scholar]

47. Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med. 1985;313:353–360. [PubMed] [Google Scholar]

48. Foulis AK, Farquharson MA. Aberrant expression of HLA-DR antigens by insulin-containing beta-cells in recent-onset type I diabetes mellitus. Diabetes. 1986;35:1215–1224. [PubMed] [Google Scholar]

49. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia. 2009;52:1143–1151. [PubMed] [Google Scholar]

50. Bonner-Weir S. Beta-cell turnover: its assessment and implications. Diabetes. 2001;50(Suppl. 1):S20–S24. [PubMed] [Google Scholar]

51. Henquin JC, Rahier J. Pancreatic alpha cell mass in European subjects with type 2 diabetes. Diabetologia. 2011;54:1720–1725. [PMC free article] [PubMed] [Google Scholar]

52. Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, Butler PC. β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care. 2013;36:111–117. [PMC free article] [PubMed] [Google Scholar]

53. Rahier J, Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. Diabetologia. 1983;24:366–371. [PubMed] [Google Scholar]

54. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10(Suppl. 4):32–42. [PubMed] [Google Scholar]

55. Campbell-Thompson M, Wasserfall C, Montgomery EL, Atkinson MA, Kaddis JS. Pancreas organ weight in individuals with disease-associated autoantibodies at risk for type 1 diabetes. JAMA. 2012;308:2337–2339. [PubMed] [Google Scholar]

56. Kin T, Murdoch TB, Shapiro AM, Lakey JR. Estimation of pancreas weight from donor variables. Cell Transplant. 2006;15:181–185. [PubMed] [Google Scholar]

57. MacLean N, Ogilvie RF. Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes. 1955;4:367–376. [PubMed] [Google Scholar]

58. Foulis AK, Stewart JA. The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue. Diabetologia. 1984;26:456–461. [PubMed] [Google Scholar]

59. Williams AJ, Thrower SL, Sequeiros IM, et al. Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes. J Clin Endocrinol Metab. 2012;62:2595–2604. [PubMed] [Google Scholar]

60. Gaglia JL, Guimaraes AR, Harisinghani M, et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest. 2011;121:442–445. [PMC free article] [PubMed] [Google Scholar]

61. Rowe P, Wasserfall C, Croker B, et al. Increased complement activation in human type 1 diabetes pancreata. Diabetes Care. 2013;36:3815–3817. [PMC free article] [PubMed] [Google Scholar]

62. Sarkar SA, Lee CE, Victorino F, et al. Expression and regulation of chemokines in murine and human type 1 diabetes. Diabetes. 2012;61:436–446. [PMC free article] [PubMed] [Google Scholar]

63. Reddy S, Zeng N, Al-Diery H. Analysis of peri-islet CD45-positive leucocytic infiltrates in longstanding type 1 diabetic patients. Diabetologia. 2015;58:1024–1035. [PubMed] [Google Scholar]

64. Piran R, Lee SH, Li CR, Charbono A, Bradley LM, Levine F. Pharmacological induction of pancreatic islet cell transdifferentiation: relevance to type I diabetes. Cell Death Dis. 2014;5:e1357. [PMC free article] [PubMed] [Google Scholar]

65. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;58:1024–1035. [PMC free article] [PubMed] [Google Scholar]

66. Marhfour I, Lopez XM, Lefkaditis D, et al. Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. Diabetologia. 2012;55:2417–2420. [PubMed] [Google Scholar]

67. Morgan NG, Richardson SJ. Enteroviruses as causative agents in type 1 diabetes: loose ends or lost cause? Trends Endocrinol Metab. 2014;25:611–619. [PubMed] [Google Scholar]

Can Diabetics Donate Blood?

You can donate blood if you have diabetes, but you’ll need to meet certain requirements. If your diabetes is well managed, you can donate once every 56 days.

Donating blood is a selfless way to help others. Blood donations help people who need transfusions for many types of medical conditions, and you may decide to donate blood for a variety of reasons.

A pint of donated blood may help up to three people. Although you’re allowed to donate blood if you have diabetes, there are a few requirements that you’ll need to meet.

If you have diabetes and want to donate blood, it’s generally safe to do so. People with type 1 and type 2 diabetes are eligible to give blood donations. But you should properly manage your diabetes and be in otherwise good health before donating blood.

Properly managing your diabetes means that you maintain healthy blood sugar levels. This requires you to be vigilant about your diabetes daily. You need to be aware of your blood sugar levels throughout each day and make sure you eat a nutritious diet and exercise sufficiently.

Living a healthy lifestyle will contribute to keeping your blood sugar levels in a healthy range. Your doctor may also prescribe certain medications to help manage your diabetes. These medications shouldn’t impact your ability to donate blood.

If you want to donate blood but are concerned about your diabetes, talk with your doctor before your donation. They can answer any questions you may have and help you determine whether this is the best option for you.

Health screening

Blood donation centers have a screening process that requires you to disclose any preexisting health conditions.

It’s also when a certified Red Cross professional will evaluate you and measure your basic vital statistics, such as:

  • temperature
  • pulse
  • blood pressure
  • hemoglobin levels

If you have diabetes, you’ll need to share your condition at the screening. The person screening you may ask additional questions.

You should make sure you have information about any medications you may be taking to treat your diabetes. These diabetes medications shouldn’t disqualify you from donating blood.

People who donate blood, regardless of whether they have diabetes, must also meet the following requirements:

  • be in good health in general and on the day you donate
  • weigh at least 110 pounds
  • be 16 years or older (age requirement varies by state)

You should reschedule your session if you aren’t feeling well on the day of your blood donation.

Other health conditions and factors, such as international travel, may prevent you from donating blood. Check with your blood donation center if there are other considerations, health or otherwise, that may prevent you from donating.

Blood donation

The entire blood donation process takes about 1 hour and 15 minutes. The time spent actually donating blood typically takes about 10 minutes.

You’ll be seated in a comfortable chair while you donate blood. The person assisting you with the donation will sanitize your arm and insert a needle. Generally, the needle will only cause a slight amount of pain, similar to a pinch.

After the needle goes in, you shouldn’t feel any pain.

Before you decide to donate blood, there are a few ways you can prepare to make sure your donation is successful. You should:

  • Drink plenty of water leading up to the donation. You should increase your water intake a few days before your scheduled donation.
  • Eat iron-rich foods or take an iron supplement 1 to 2 weeks before the donation.
  • Sleep well the night before your donation. Plan on getting 8 or more hours of sleep.
  • Eat balanced meals leading up to your donation and afterward. This is especially important when you have diabetes. Maintaining a healthy diet that keeps your blood glucose levels low is key to managing your condition.
  • Limit caffeine on donation day.
  • Bring a list of the medications you’re currently taking.
  • Carry identification with you, such as your driver’s license or two other forms of identification.

After the donation, you should monitor your blood sugar level and continue to eat a healthy diet. Consider adding iron-rich foods or a supplement to your diet for 2 to 4 weeks following your donation.

In general, you should:

  • Take acetaminophen if your arm feels sore.
  • Keep your bandage on for at least 4 hours to avoid bruising.
  • Rest if you feel lightheaded.
  • Avoid strenuous activity for 24 hours after the donation. This includes exercise as well as other tasks.
  • Increase your fluid intake for a few days following your donation.

If you feel sick or are concerned about your health after the blood donation, contact your doctor immediately.

Donating blood is an altruistic endeavor that can directly help people. Living with well-managed diabetes shouldn’t prevent you from donating blood on a regular basis.

If your diabetes is well managed, you can donate once every 56 days.

If you begin experiencing unusual symptoms after donating, you should speak with your doctor.

Can people with diabetes become blood donors?

« MiniMed Care Blog | March 15, 2022 |

Adviсe

According to the World Health Organization, “Blood is the most valuable thing a person can give to another person. This is the gift of life.” Donated blood is used around the world to save the lives of people injured in accidents or other injuries, cancer patients, children with severe iron deficiency and women who develop life-threatening complications during pregnancy and childbirth 1 .

If you want to save someone’s life, blood donation is a great opportunity. However, it is important for the safety of both the donor and the recipient of any blood product that blood donors undergo rigorous screening. What does this mean for people with diabetes?

6 things to know about the impact of blood donation on the body of a person with diabetes

Notably, regular blood donation has some positive health effects. According to research, frequent blood donation contributes to the following:

1. Reducing the risk of diabetes by preventing iron overload 2 .

2. Reduced insulin resistance in both type 2 diabetic and non-diabetic people with high iron blood levels 2 .

However, there are some risks associated with donating blood for people with diabetes. These include the possible development of the following conditions:

3. Hypotension (a sharp decrease in blood pressure) 2 , which poses a risk to both patients with diabetes and people without such a diagnosis. However, if you have diabetes, autonomic neuropathy poses a higher risk of hypotension 3 .

4. Hypoglycemia (a sharp drop in blood sugar) 2 . This is another condition that occurs not only in people with diabetes and can lead to serious consequences.

5. Decrease in the level of glycated hemoglobin. This seems to be more of a plus, but such a decrease does not reflect your actual glycemic status and may cause you to incorrectly treat your diabetes 3 .

6. On the other hand, blood transfusions in people with diabetes can also falsely lower their glycated hemoglobin values ​​due to mixing of donor RBCs 2 .

Can I donate blood if I have diabetes?

The answer to this question depends on two things:

  • where you live;
  • therapies you use for diabetes.

There is currently no consensus on whether people with diabetes can donate blood. The World Health Organization recommends donating blood only for people with diabetes that is controlled by diet and oral medications.

Therefore, these guidelines exclude patients with type 1 diabetes on insulin therapy. However, the American Red Cross 2 as well as the Australian Red Cross Blood Service 4 allow people with diabetes who are on insulin therapy to donate. At present, it is believed in most countries that there is insufficient evidence to support the safety of blood donation in people with insulin-dependent diabetes, leading many to be overly cautious 2 .

It is worth noting that in order to become a donor and save lives, you need to meet other criteria that are not related to diabetes. Even if your medical conditions allow you to donate blood in your country, you may be refused at certain times due to, for example, being too low weight or having a recent heart attack (not to mention that after a heart attack you are unlikely to want to donate blood at all).

Conclusion

It is noble to be a blood donor. However, if you have been diagnosed with diabetes, it is important to think about your own health and safety when donating blood. If you want to donate blood, talk to your diabetes doctors about the donor criteria in your country and how safe it is for you to donate blood. Remember: your health is above all!

References

  1. World Health Organization. Blood products: blood donation. https://www.who.int/. 2021. Available at: https://www.who.int/news-room/q-a-detail/blood-products-why-should-i-donate-blood. (Accessed January 2022).
  2. Debecho D, Hailu A. Assessment of Blood Donation Safety by People Diagnosed with Diabetes, Hypertension, Malaria, and Cancer. JAMMR. 2019;29(10):1-8.
  3. JPAC. Change Notification No 07 2021 – Diabetes Mellitus WBDSG. https://www.transfusionguidelines.org/. 2021.
  4. Australian Red Cross Lifeblood. FAQ Diabetes. https://www.donateblood.com.au/. 2021. Available at: https://www.donateblood.com.au/faq/diabetes. (Accessed January 2022).

Contraindications for donation

SURVEY

Before donating blood, the donor undergoes a free medical examination, which includes an examination by a transfusiologist and a preliminary laboratory test. Body temperature measured before blood donation should not exceed 37°C; allowable systolic pressure – from 90 to 149 mm Hg, diastolic – from 60 to 89 mm Hg; the allowable heart rate is 55-95 beats per minute.

If you have a disease not included in the list below, or you are taking any medications or dietary supplements, tell your doctor. Examination and conversation between a doctor and a donor are mandatory procedures before donating blood or its components. Do not hide your ailments from the doctor, answer his questions and the questionnaire honestly, and then donation will be safe both for you and for those who need a transfusion.

PERMANENT CONTRAINDICATIONS

(withdrawal from donation, regardless of the duration of the disease and the results of treatment)

1. Infectious and parasitic diseases:

  • Disease caused by the human immunodeficiency virus (HIV), hepatitis B and C viruses

  • Syphilis, congenital or acquired

  • Tuberculosis (all forms)

  • Repeated positive test result for markers of disease caused by human immunodeficiency virus (HIV) infection

  • Repeated positive test result for markers of viral hepatitis B and C

  • Repeated positive test result for markers of the causative agent of syphilis

2. Malignant neoplasms

3. Diseases of the blood, hematopoietic organs and individual disorders involving the immune mechanism

4. Diseases of the central nervous system (organic disorders)

5. Complete absence of hearing and (or) speech, and (or) vision

6. Mental disorders and behavioral disorders in a state of exacerbation and (or) representing a danger to the patient and others

7. Mental and behavioral disorders due to substance use

8. Diseases of the circulatory system:

hypertensive (hypertonic) disease II-III stage, coronary heart disease, obliterating endoarteritis, nonspecific aortoarteritis, phlebitis and thrombophlebitis, endocarditis, myocarditis, heart disease (congenital, acquired)

9. Diseases of the respiratory system:

bronchial asthma, bronchiectasis, pulmonary emphysema

10. Diseases of the digestive system:

Achilles gastritis, chronic liver diseases, including unspecified, toxic liver damage, calculous cholecystitis with recurring attacks and cholangitis, liver cirrhosis

11. Diseases of the genitourinary system in the stage of decompensation:

diffuse and focal lesions of the kidneys, urolithiasis

12. Connective tissue diseases, as well as acute and (or) chronic osteomyelitis

13. Radiation sickness

14. Diseases of the endocrine system in the stage of decompensation

15. Diseases of the eye and adnexa:

Uveitis, iritis, iridocyclitis, chorioretinal inflammation, trachoma, myopia of 6 diopters or more)

16. Diseases of the skin and subcutaneous tissue:

Psoriasis, erythema, eczema, pyoderma, sycosis, pemphigus (pemphigus), dermatophytosis, furunculosis

17. Surgical interventions (resection, amputation, removal of an organ (stomach, kidney, spleen, ovaries, uterus, etc.)) organ and tissue transplantation resulting in permanent disability (I and II disability groups), organ xenotransplantation

18. Permanent disability (I and II disability group)

19. Female donor for donation of 2 RBCs or apheresis suspension

20. Individuals with repeated non-specific reactions to markers of human immunodeficiency viruses, hepatitis B and C, and the causative agent of syphilis

21. Persons with re-identified alloimmune antibodies to erythrocyte antigens (excluding plasma donors for the production of drugs)

22. Persons with repeated detected anti-A1 extraagglutinins (with the exception of plasma donors for the production of drugs)

TEMPORARY CONTRAINDICATIONS

NAMES WITHDRAWAL FROM DONATION
1. Body weight less than 50 kg Up to a body weight of 50 kg
2. Age under 20 years (for donation of 2 RBCs or apheresis suspension) Until age 20
3. Body weight less than 70 kg (for donation of 2 RBCs or apheresis suspension) Up to a body weight of 70 kg
4. Hemoglobin less than 140 g/l (for donation of 2 RBCs or apheresis suspension) Until hemoglobin reaches 140 g/l
5. Body temperature above 37°C Before normalization of body temperature (37 ° C and below)
6. Pulse – less than 55 beats per minute and more than 95 beats per minute Until the pulse normalizes from 55 to 95 beats per minute
7. Blood pressure:
systolic less than 90 mm Hg. Art. and more than 149 mm Hg. Art.;
diastolic – less than 60 mm Hg. Art. and more than 89 mm Hg. Art.		 Before normalization
systolic pressure: 90 – 149 mm Hg. Art.;

diastolic pressure: 60 – 89 mmHg Art.

8. Body Mass Index Less than 18.5 and more than 40
9. Discrepancy between the results of the study of blood type AB0, Rh affiliation, antigens C, c, E, e, K with the results of the study during the previous donation Before performing a confirmatory study
10. Transfusion of blood and (or) its components 120 calendar days from the date of transfusion
11. Primary detection in a blood sample of a donor of alloimmune antibodies to erythrocyte antigens Until confirmation of the absence of alloimmune antibodies to erythrocyte antigens in the blood sample of the donor, not earlier than 180 calendar days after the initial detection
12. Surgical interventions, including artificial termination of pregnancy 120 calendar days from the day of surgery
13. Therapeutic and cosmetic procedures with violation of the skin (tattoo, piercing, acupuncture, etc.) 120 calendar days from the end of the procedures
14. Contact with carriers and patients with viral hepatitis B or C, syphilis, human immunodeficiency virus disease (HIV infection) 120 calendar days after the end of the last contact
15. Questionable result for markers of viral hepatitis B and (or) viral hepatitis C, and (or) human immunodeficiency virus (HIV) disease, and (or) syphilis Until confirmation of the absence of markers of viral hepatitis B and (or) viral hepatitis C, and (or) the disease caused by the human immunodeficiency virus (HIV infection), and (or) the causative agent of syphilis, but not earlier than 120 calendar days after receiving questionable lab result
16. Transferred infectious diseases:
– a history of malaria in the absence of symptoms and in the presence of negative results of immunological tests 3 years
– typhoid fever after recovery and complete clinical examination in the absence of severe functional disorders 1 year
– sore throat, influenza, acute respiratory viral infection 30 calendar days after recovery
17. Past infectious and parasitic diseases not listed in the list of permanent and temporary contraindications 120 calendar days after recovery
18. Acute or chronic inflammatory processes in the acute stage, regardless of localization 30 calendar days after the relief of the acute period
19. Exacerbation of gastric and (or) duodenal ulcers 1 year from the moment of relief of the acute period
20. Kidney diseases not listed in paragraph 12 of the list of permanent contraindications 1 year from the moment of relief of the acute period
21. Allergic diseases in the acute stage 60 calendar days after stopping the acute period
22. Period of pregnancy, lactation 1 year after childbirth, 90 calendar days after the end of lactation
23. Vaccination:
– vaccination with inactivated vaccines (including against tetanus, diphtheria, whooping cough, paratyphoid, cholera, influenza), toxoids 10 calendar days after vaccination
– vaccination with live vaccines (including against brucellosis, plague, tularemia, tuberculosis, smallpox, rubella, poliomyelitis orally), the introduction of tetanus toxoid (in the absence of severe inflammation at the injection site) 30 calendar days after vaccination
– vaccination with recombinant vaccines (including against viral hepatitis B, coronavirus infection) 30 calendar days after vaccination
– introduction of immunoglobulin against hepatitis B 120 calendar days after vaccination
– introduction of immunoglobulin against tick-borne encephalitis 120 calendar days after vaccination
– vaccination against rabies 1 year after vaccination
24. Taking medications:
– antibiotics 14 calendar days after the end of admission
– analgesics, anticoagulants, antiplatelet agents (including salicylates) 3 calendar days after the end of admission
25. Drinking alcohol 48 hours